215 related articles for article (PubMed ID: 7569681)
1. Cytokeratin fragment 21-1 in gynecologic malignancy: comparison with cancer antigen 125 and squamous cell carcinoma-related antigen.
Inaba N; Negishi Y; Fukasawa I; Okajima Y; Ota Y; Tanaka K; Matsui H; Iwasaki H; Sudo H; Tanaka N
Tumour Biol; 1995; 16(6):345-52. PubMed ID: 7569681
[TBL] [Abstract][Full Text] [Related]
2. Serum CYFRA 21-1 assay in squamous cell carcinoma of the cervix.
Ferdeghini M; Gadducci A; Annicchiarico C; Prontera C; Malagnino G; Castellani C; Facchini V; Bianchi R
Anticancer Res; 1993; 13(5C):1841-4. PubMed ID: 7505543
[TBL] [Abstract][Full Text] [Related]
3. Clinical evaluation of serum sialosyl-Tn antigen levels in comparison with CA 125 levels in gynecologic cancers.
Ryuko K; Iwanari O; Nakayama S; Iida K; Kitao M
Cancer; 1992 May; 69(9):2368-78. PubMed ID: 1562985
[TBL] [Abstract][Full Text] [Related]
4. A combination of serum tumor markers identifies high-risk patients with early-stage squamous cervical cancer.
Davelaar EM; van de Lande J; von Mensdorff-Pouilly S; Blankenstein MA; Verheijen RH; Kenemans P
Tumour Biol; 2008; 29(1):9-17. PubMed ID: 18497544
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of pretreatment serum Cyfra 21-1, tissue polypeptide antigen, and squamous cell carcinoma antigen levels in patients with cervical cancer.
Gaarenstroom KN; Bonfrer JM; Kenter GG; Korse CM; Hart AA; Trimbos JB; Helmerhorst TJ
Cancer; 1995 Sep; 76(5):807-13. PubMed ID: 8625184
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of cytokeratin 19 fragments in cervical cancer.
Nasu K; Etoh Y; Yoshimatsu J; Matsu T; Narahara H; Miyakawa I
Gynecol Obstet Invest; 1996; 42(4):267-70. PubMed ID: 8979101
[TBL] [Abstract][Full Text] [Related]
7. The clinical relevance of serum CYFRA 21-1 assay in patients with ovarian cancer.
Gadducci A; Ferdeghini M; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Int J Gynecol Cancer; 2001; 11(4):277-82. PubMed ID: 11520365
[TBL] [Abstract][Full Text] [Related]
8. CYFRA 21-1 as a tumor marker used in measuring the serum fragment of cytokeratin subunit 19 by immunoradiometric assay.
Sarwar M; Tomiyoshi K; Inoue T; Fukazawa K; Endo K
Ann Nucl Med; 1994 Nov; 8(4):301-6. PubMed ID: 7535552
[TBL] [Abstract][Full Text] [Related]
9. Serum tumor markers in the management of ovarian, endometrial and cervical cancer.
Gadducci A; Cosio S; Carpi A; Nicolini A; Genazzani AR
Biomed Pharmacother; 2004 Jan; 58(1):24-38. PubMed ID: 14739059
[TBL] [Abstract][Full Text] [Related]
10. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
11. Serum fragment of cytokeratin subunit 19 measured by CYFRA 21-1 immunoradiometric assay as a marker of lung cancer.
Pujol JL; Grenier J; Daurès JP; Daver A; Pujol H; Michel FB
Cancer Res; 1993 Jan; 53(1):61-6. PubMed ID: 7677981
[TBL] [Abstract][Full Text] [Related]
12. Serum level of macrophage colony-stimulating factor as a marker for gynecologic malignancies.
Suzuki M; Ohwada M; Sato I; Nagatomo M
Oncology; 1995; 52(2):128-33. PubMed ID: 7854772
[TBL] [Abstract][Full Text] [Related]
13. [Basic and clinical studies on serum cytokeratin 19 fragment assay using Centocor CYFRA 21-1 kit in patients with lung cancer].
Hamase A; Sugimoto Y; Maeda M; Kitani H; Fukuchi M
Kaku Igaku; 1994 Aug; 31(8):969-76. PubMed ID: 7523748
[TBL] [Abstract][Full Text] [Related]
14. CYFRA 21-1 enzyme-linked immunosorbent assay. Evaluation as a tumor marker in non-small cell lung cancer.
Lai RS; Hsu HK; Lu JY; Ger LP; Lai NS
Chest; 1996 Apr; 109(4):995-1000. PubMed ID: 8635383
[TBL] [Abstract][Full Text] [Related]
15. CYFRA 21-1 in lung cancer: comparison with CEA, CA 125, SCC and NSE serum levels.
Molina R; Agusti C; Mañe JM; Filella X; Jo J; Joseph J; Giménez N; Estapé J; Ballesta AM
Int J Biol Markers; 1994; 9(2):96-101. PubMed ID: 7523548
[TBL] [Abstract][Full Text] [Related]
16. Determination of serum levels of different cytokeratins in patients with uterine malignancies.
Ferdeghini M; Gadducci A; Prontera C; Castellani C; Annicchiarico C; Gagetti O; Facchini V; Bianchi R
Anticancer Res; 1994; 14(3B):1393-7. PubMed ID: 7520682
[TBL] [Abstract][Full Text] [Related]
17. Cyfra 21-1 as a biologic marker of non-small cell lung cancer. Evaluation of sensitivity, specificity, and prognostic role.
Wieskopf B; Demangeat C; Purohit A; Stenger R; Gries P; Kreisman H; Quoix E
Chest; 1995 Jul; 108(1):163-9. PubMed ID: 7541742
[TBL] [Abstract][Full Text] [Related]
18. Clinical usefulness of CYFRA assay in diagnosing lung cancer: measurement of serum cytokeratin fragment.
Sugama Y; Kitamura S; Kawai T; Ohkubo A; Hasegawa S; Kuriyama T; Kato H; Fukuoka M; Ohkawa J
Jpn J Cancer Res; 1994 Nov; 85(11):1178-84. PubMed ID: 7530241
[TBL] [Abstract][Full Text] [Related]
19. CYFRA 21-1 serum levels in women with adnexal masses and inflammatory diseases.
Tempfer C; Hefler L; Heinzl H; Loesch A; Gitsch G; Rumpold H; Kainz C
Br J Cancer; 1998 Oct; 78(8):1108-12. PubMed ID: 9792159
[TBL] [Abstract][Full Text] [Related]
20. Assessment of serum CYFRA 21-1 in lung cancer.
Muraki M; Tohda Y; Iwanaga T; Uejima H; Nagasaka Y; Nakajima S
Cancer; 1996 Apr; 77(7):1274-7. PubMed ID: 8608502
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
